Table.

Details of included studies of treatment of toxoplasmosis in pregnant women

Study	Trimester	Inclusion criteria	Selection of controls	Quality score	Regimen	No of infected children	No not infected	No lost to follow up	% Infected children (95% CI)
Desmonts and Couvreur21	All	Seroconversion; significant increase in IgG; clinical signs and high levels of IgG	Unknown; historical controls (seroconversion diagnosed retrospectively, after delivery)	3	Spiramycin (2-3 g/day) for at least 1 month: 388	88	297	3	22 (18 to 27)
					No treatment: 154	85	60	9	52 (44 to 60)
Douche et al18	All	Seroconversion	Late seroconversions Inadequate follow up	4	Spiramycin (2g/day): 64 spiramycin + pyrimethamine + sulphadiazine after positive fetal diagnosis: 5	9	60	0	13 (6 to 24)
					No treatment: 29	29	0	0	100 (63 to 100)
Excler et al20	First	Seroconversion; increase in IgG	Unknown	2	Spiramycin (3 g/day): 31	2	29	0	6 (1 to 23)
					No treatment: 4	0	4	0	0 (0 to 60)
	Second				Spiramycin: 55	15	40	0	27 (16 to 41)
					No treatment: 13	5	8	0	38 (15 to 68)
	Third				Spiramycin: 18	5	13	0	28 (11 to 54)
					No treatment: 13	9	4	0	69 (39 to 90)
	All				Spiramycin: 104	22	82	0	21 (14 to 30)
					No treatment: 30	14	16	0	47 (29 to 65)
Knerer et al19	14-29 week	Seroconversion	Untreated patients or non-compliers	4	Spiramycin (3 g/day): 9	0	9	0	0 (0 to 37)
					No treatment: 2	2	0	0	100 (20 to 100)
Kräubig et al25	All	Seroconversion (18); increase (x2) dye test; dye test >1000	Unknown	4	Pyrimethamine+sulphonamide: 59	3	56	0	5 (1 to 15)
					No treatment: 84	14	70	0	17 (10 to 27)
Lambotte et al23	All	Seroconversion	Untreated patients or non-compliers	4	Spiramycin + sulphadiazine (3 g/day each to 4 weeks/6): 28 No treatment: 101	0	28	0	0 (0 to 15)
						10	91	0	10 (5 to 18)
Roux et al22	All	Seroconversion (10); evolutive infection* (18); high IgG titres (25)	Late seroconversions (5) Inadequate follow up (1)	3	Spiramycin (3 g/day): 47	2	43	2	4 (0.7 to 15)
					No treatment: 6	5	1	0	83 (36 to 99)
Thoumsin et al24	All	Seroconversion	Unknown	2	Spiramycin + pyrimethamine + suphadiazine (dose unknown): 99	10	89	0	10 (5 to 8)
					No treatment: 101	10	91	0	10 (5 to 20)
Wallon et al26	All	Seroconversion	Lyons: No controls Copenhagen: screening at delivery	4	Spiramycin (3 g/day) ± pyrimethamine and sulphadiazine: 564	141	381	42	24 (20 to 27)
					No treatment : 125	26	99	0	21 (14 to 29)

^* Increase in IgG and IgM titres or loss of IgM with stable or increasing IgG titre.